目次

1. Introduction to Poly (ADP-Ribose) Polymerase Inhibitors
1.1 PARP Inhibitors as Unique Cancer Therapy
1.2 Evolutionary Aspects of PARP Inhibitors

2. PARP Proteins: An Attractive Target for Developing Cancer Therapeutics
2.1 Structural Organization of Target Site of PARP Inhibitors
2.2 Structural Organization of PARP Inhibitors

3. Therapeutic Exploitation of Role of PARP Proteins in Normal Cells and Cancer Cells
3.1 Significance of PARP Proteins in Normal Cells
3.2 Significance of PARP Proteins in Tumorgenesis: Affecting Cell Division and DNA
3.3 Repair
3.4 PARP Inhibitors: Distinct Modes of Action for Eliminating Cancer Cells

4. Global PARP Inhibitor Market Outlook
4.1 Current Market Scenario
4.2 Future Market Opportunity

5. PARP Inhibitor Market Opportunity by Region
5.1 US
5.2 Europe
5.3 China
5.4 Japan

6. Olaparib (Lynparza) - 1st Approved PARP Inhibitor; 2014
6.1 Overview
6.2 Patent Exclusivity
6.3 Pricing and Dosage
6.4 Sales Analysis

7. Rucaparib (Rubraca) - 2nd Approved PARP Inhibitor; 2016
7.1 Overview
7.2 Patent Exclusivity
7.3 Pricing and Dosage
7.4 Sales Analysis

8. Niraparib (Zejula) - 3rd Approved PAPR Inhibitor; 2017
8.1 Overview
8.2 Patent Exclusivity
8.3 Pricing and Dosage
8.4 Sales Analysis

9. Talazoparib (Talzenna) - 4th Approved PARP Inhibitor; 2018
9.1 Overview
9.2 Patent Exclusivity
9.3 Pricing and Dosage

10. Fuzuloparib (AiRuiYi) - 5th Approved PARP Inhibitor; 2020

11. Pamiparib (Partruvix) - 6th Approved PARP Inhibitor; 2021

12. PARP Inhibitors - Sales Forecast Till 2028
12.1 Lynparza
12.2 Rubraca
12.3 Zejula
12.4 Talzenna

13. Approved PARP Inhibitors Reimbursement Policy
13.1 Lynparza Reimbursement Policy
13.2 Rubraca Reimbursement Policy
13.3 Zejula Reimbursement Policy
13.4 Talzenna Reimbursement Policy

14. PARP Inhibitor Clinical Trial Insight
14.1 Company
14.2 Country
14.3 Indication
14.4 Indication

15. Global Poly(ADP-Ribose) Polymerase Inhibitors Clinical Trials By Company, Indication and Phase
15.1 Preclinical
15.2 Phase-I
15.3 Phase-I/II
15.4 Phase-II
15.5 Phase-II/III
15.6 Phase-III

16. Marketed Poly(ADP-Ribose) Polymerase Inhibitors Clinical insights

17. PARP Inhibitors with Conventional Cancer Therapy: Efficacy and Dosage Analysis
17.1 PARP Inhibitors with Chemotherapy
17.1.1 Temozolomide
17.1.2 Platinum Salts
17.1.3 Taxanes
17.1.4 Gemcitabine
17.1.5 Topoisomerase Iinhibitors
17.2 PARP Inhibitors in Combination with Radiotherapy

18. Improved Efficacy of PARP Inhibitors by Modern Cancer Therapies
18.1 Combination of PARP Inhibitors and Targeted Therapies
18.1.1 PARP Inhibitors with EGFR Inhibitors
18.1.2 PARP Inhibitors with VEGFR Inhibitors
18.1.3 PARP Inhibitors with PI3K/mTOR Inhibitors
18.1.4 PARP Inhibitors with Trastuzumab
18.1.5 Anti-endocrine agents
18.1.6 HSP90 Inhibitors
18.1.7 IGF-1R and HDAC Inhibitors
18.2 PARP Inhibitors in Combination with Immunotherapies

19. Global PARP Inhibitors Market Dynamics
19.1 Drivers
19.2 Market Challenges

20. PARP Inhibitor Market Future Perspective

21. Competitive Landscape
21.1 2X Oncology
21.2 Abott Laboratories
21.3 Allarity Therapeutics
21.4 AstraZeneca
21.5 BeiGene
21.6 Bristol Myers Squibb
21.7 Cephalon
21.8 Clovis Oncology
21.9 Eisai Co. Ltd
21.10 GlaxoSmithKline
21.11 IMPACT Therapeutics
21.12 Jeil Pharmaceuticals
21.13 KuDOS Pharmaceuticals
21.14 Kyowa Hakko Kirin
21.15 Lead Therapeutics
21.16 Ono Pharmaceutical
21.17 Pfizer

List of Figures & Tables
Figure 1-1: Biochemistry and Biological Functions of Poly ADP-Ribosylation Reaction Mediated by Poly (ADP-Ribose) Polymerase (PARP) Enzymes
Figure 1-2: History and Evolution of PARP Inhibitors
Figure 2-1: Structural Organization of PARP-1 and PARP-2 Enzymes
Figure 3-1: PARP Proteins in DNA Damage Repair Mechanism
Figure 3-2: Importance of PARP in DNA Repair Mechanism in Normal Cells
Figure 3-3: Dual Action of PARP inhibition for Cancer Treatment
Figure 4-1: Global - Cancer Incidences and Deaths (Million), 2020
Figure 4-2: Global - PARP Inhibitor Market Size (US$ Million), 2017-2021
Figure 4-3: Global - PARP Inhibitor Market by Drug Type (US$ Million), 2021
Figure 4-4: Global - PARP Inhibitor Market by Drug Type (US$ Million), 2020
Figure 4-5: Global - PARP Inhibitor Market by Drug Type (%), 2021
Figure 4-6: Global - PARP Inhibitor Market by Drug Type (%), 2020
Figure 4-7: Global - PARP Inhibitor Market Size (US$ Billion), 2022 - 2028
Figure 5-1: US - Cancer Incidences and Deaths (Million), 2020 and 2030
Figure 5-2: US - PARP Inhibitor Market Size (US$ Million), 2020 and 2021
Figure 5-3: US vs. ROW - PARP Inhibitor Market Size (US$ Million), 2021
Figure 5-4: US vs. ROW - PARP Inhibitor Market Size (%), 2021
Figure 5-5: US - PARP Inhibitor Market Size (US$ Million), 2022 - 2028
Figure 5-6: Europe - Cancer Incidences and Deaths (Million), 2020 and 2030
Figure 5-7: Europe - PARP Inhibitor Market Size (US$ Million), 2020 and 2021
Figure 5-8: Europe vs. ROW - PARP Inhibitor Market Size (US$ Million), 2021
Figure 5-9: Europe vs. ROW - PARP Inhibitor Market Size (%), 2021
Figure 5-10: Europe - PARP Inhibitor Market Size (US$ Million), 2022 - 2028
Figure 5-11: China - Cancer Incidences and Deaths (Million), 2020 and 2030
Figure 5-12: China - PARP Inhibitor Market Size (US$ Million), 2020 and 2021
Figure 5-13: China vs. ROW - PARP Inhibitor Market Size (US$ Million), 2021
Figure 5-14: China vs. ROW - PARP Inhibitor Market Size (%), 2021
Figure 5-15: China - PARP Inhibitor Market Size (US$ Million), 2022 - 2028
Figure 5-16: Japan - Cancer Incidences and Deaths (Million), 2020 and 2030
Figure 5-17: Japan - PARP Inhibitor Market Size (US$ Million), 2020 and 2021
Figure 5-18: Japan - PARP Inhibitor Market Size (US$ Million), 2022 - 2028
Figure 6-1: US - Olaparib FDA Orphan Designation Year by Indication
Figure 6-2: US - Lynparza FDA Approval Year by Indication
Figure 6-3: Europe - Lynparza EMA Year by Indication
Figure 6-4: Lynparza - Initial Approval Year by Region
Figure 6-5: US - Lynparza Patent by Assignee
Figure 6-6: US - Lynparza Patent Approval and Expiration Year
Figure 6-7: Lynparza - Patent Exclusivity Year by Region
Figure 6-8: US - Cost of Supply of 60 Tablets and Per Unit Cost of Lynparza Oral Tablet (US$), May’2022
Figure 6-9: US - Cost of Supply of 120 Tablets and Per Unit Cost of Lynparza Oral Tablet (US$), May’2022
Figure 6-10: UK - Cost of Supply of 56 Tablets and Per Unit Cost of Lynparza Oral Tablet (GBP/US$), May’2022
Figure 6-11: Lynparza - Recommended Initial and Dose Reductions (mg/day)
Figure 6-12: Lynparza - Cost of Daily and Annual Cost of Treatment (US$), May’2022
Figure 6-13: Global - Lynparza Annual Sales (US$ Million), 2018 - 2021
Figure 6-14: US - Lynparza Annual Sales (US$ Million), 2018 - 2021
Figure 6-15: Europe - Lynparza Annual Sales (US$ Million), 2018 - 2021
Figure 6-16: ROW - Lynparza Annual Sales (US$ Million), 2018 - 2021
Figure 6-17: Lynparza - Annual Sales by Region (US$ Million), 2021
Figure 6-18: Lynparza - Annual Sales by Region (%), 2021
Figure 6-19: Global - Lynparza Quarterly Sales (US$ Million), 2021
Figure 6-20: Global - Lynparza Quarterly Sales (US$ Million), 2020
Figure 7-1: US - Rucaparib FDA Orphan Designation and Patent Exclusivity Year
Figure 7-2: US - Rubraca FDA Approval Year by Indication
Figure 7-3: Rubraca - Approval Year by Region
Figure 7-4: US - Lynparza Patent Approval and Expiration Year
Figure 7-5: US - Cost of Supply of 60 Tablets and Per Unit Cost of Rubraca Oral Tablet (US$), May’2022
Figure 7-6: Europe - Cost of Supply of 60 Tablets and Per Unit Cost of Rubraca 200mg Oral Tablet (Euro/US$), May’2022
Figure 7-7: Europe - Cost of Supply of 60 Tablets and Per Unit Cost of Rubraca 300mg Oral Tablet (Euro/US$), May’2022
Figure 7-8: Rubraca - Recommended Initial and Dose Reductions (mg/day)
Figure 7-9: Rubraca - Recommended Maximum and Minimum Dose (mg/day)
Figure 7-10: Rubraca - Cost of Daily and Annual Cost of Treatment (US$), May’2022
Figure 7-11: Global - Rubraca Annual Sales (US$ Million), 2018 - 2021
Figure 7-12: US - Rubraca Annual Sales (US$ Million), 2018 - 2021
Figure 7-13: Europe - Rubraca Annual Sales (US$ Million), 2019 - 2021
Figure 7-14: Rubraca - Annual Sales by Region (US$ Million), 2021
Figure 7-15: Rubraca - Annual Sales by Region (%), 2021
Figure 7-16: Rubraca - Annual Sales by Region (US$ Million), 2020
Figure 7-17: Rubraca - Annual Sales by Region (%), 2021
Figure 7-18: Global - Rubraca Quarterly Sales (US$ Million), 2021
Figure 7-19: US - Rubraca Quarterly Sales (US$ Million), 2021
Figure 7-20: Europe - Rubraca Quarterly Sales (US$ Million), 2021
Figure 8-1: US - Niraparib FDA Orphan Designation and Patent Exclusivity Year
Figure 8-2: US - Zejula FDA Approval Year by Ovarian Cancer Subtypes
Figure 8-3: Zejula - Initial Approval Year by Region
Figure 8-4: US - Zejula Patent Approval and Expiration Year
Figure 8-5: China - Zejula Patent Expiration Year
Figure 8-6: US - Cost of Supply of 30 Capsules and Per Unit Cost of Zejula Oral Capsules (US$), May’2022
Figure 8-7: US - Cost of Supply of 90 Capsules and Per Unit Cost of Zejula Oral Capsules (US$), May’2022
Figure 8-8: UK - Cost of Supply of 84, 56 Capsules and Per Unit Cost of Zejula Oral Capsule (GBP/US$), May’2022
Figure 8-9: Zejula - Recommended Initial Dose by Weight (mg/day)
Figure 8-10: Zejula - Recommended Initial and Dose Reductions (mg/day)
Figure 8-11: Zejula - Recommended Maximum and Minimum Dose (mg/day)
Figure 8-12: Zejula - Cost of Daily and Annual Cost of Treatment (US$), May’2022
Figure 8-13: Global - Zejula Annual Sales (Euro/US$ Million), 2019 - 2021
Figure 8-14: US - Zejula Annual Sales (Euro/US$ Million), 2019 - 2021
Figure 8-15: Europe - Zejula Annual Sales (Euro/US$ Million), 2019 - 2021
Figure 8-16: ROW - Zejula Annual Sales (Euro/US$ Million), 2020 and 2021
Figure 8-17: Zejula - Annual Sales by Region (Euro/US$ Million), 2021
Figure 8-18: Zejula - Annual Sales by Region (%), 2021
Figure 8-19: Global - Zejula Quarterly Sales (Euro/US$ Million), 2021
Figure 8-20: US - Zejula Quarterly Sales (Euro/US$ Million), 2021
Figure 8-21: ROW - Zejula Quarterly Sales (Euro/US$ Million), 2021
Figure 9-1: Talzenna - Approval Year by Region
Figure 9-2: US - Talzenna Patent Approval and Expiration Year
Figure 9-3: US - Talzenna Patent by Assignee
Figure 9-4: US - Cost of Supply of 30 Capsules and Per Unit Cost of Talzenna 0.25mg Oral Capsules (US$), May’2022
Figure 9-5: US - Cost of Supply of 30 Capsules and Per Unit Cost of Talzenna 0.5mg, 0.75mg, and 1mg Oral Capsules (US$), May’2022
Figure 9-6: UK - Cost of Supply of 30 Capsules and Per Unit Cost of Talzenna 0.25mg Oral Capsule (GBP/US$), May’2022
Figure 9-7: UK - Cost of Supply of 30 Capsules and Per Unit Cost of Talzenna 1mg Oral Capsule (GBP/US$), May’2022
Figure 9-8: Talzenna - Recommended Initial and Dose Reductions (mg/day)
Figure 9-9: Talzenna - Recommended Maximum and Minimum Dose (mg/day)
Figure 9-10: Talzenna - Cost of Daily and Annual Cost of Treatment (US$), May’2022
Figure 10-1: Fuzuloparib - Recommended Maximum and Minimum Dose (mg/day)
Figure 11-1: China - Partruvix Priority Review and NMPA Approval Year
Figure 12-1: Global - Lynparza Estimated Sales Value (US$ Million), 2022 - 2028
Figure 12-2: US - Lynparza Estimated Sales Value (US$ Million), 2022 - 2028
Figure 12-3: Europe - Lynparza Estimated Sales Value (US$ Million), 2022 - 2028
Figure 12-4: ROW - Lynparza Estimated Sales Value (US$ Million), 2022 - 2028
Figure 12-5: Global - Rubraca Estimated Sales Value (US$ Million), 2022 - 2028
Figure 12-6: US - Rubraca Estimated Sales Value (US$ Million), 2022 - 2028
Figure 12-7: Europe - Rubraca Estimated Sales Value (US$ Million), 2022 - 2028
Figure 12-8: Global - Zejula Estimated Sales Value (US$ Million), 2022 - 2028
Figure 12-9: US - Zejula Estimated Sales Value (US$ Million), 2022 - 2028
Figure 12-10: Europe - Zejula Estimated Sales Value (US$ Million), 2022 - 2028
Figure 12-11: ROW - Zejula Estimated Sales Value (US$ Million), 2022 - 2028
Figure 12-12: Global - Talzenna Estimated Sales Value (US$ Million), 2022 - 2028
Figure 13-1: Lynparza - Total Treatment Cost and Reimbursement Cost (US$)
Figure 13-2: Lynparza - In Pocket and Out of Pocket Cost of Treatment (%)
Figure 13-3: Rubraca - Total Treatment Cost and Reimbursement Cost (US$)
Figure 13-4: Rubraca - In Pocket and Out of Pocket Cost of Treatment (%)
Figure 13-5: Zejula - Total Treatment Cost and Reimbursement Cost (US$)
Figure 13-6: Zejula - In Pocket and Out of Pocket Cost of Treatment (%)
Figure 13-7: Zejula - Total Treatment Cost and Reimbursement Cost (US$)
Figure 13-8: Zejula - In Pocket and Out of Pocket Cost of Treatment (%)
Figure 14-1: Global - PARP Inhibitor Drugs in Clinical Trials by Company, 2022 till 2028
Figure 14-2: Global - PARP Inhibitor Drugs in Clinical Trials by Country, 2022 till 2028
Figure 14-3: Global - PARP Inhibitor Drugs in Clinical Trials by Indication, 2022 till 2028
Figure 14-4: Global - PARP Inhibitor Drugs in Clinical Trials by Phase, 2022 till 2028
Figure 17-1: Tolerable Dosage of Rucaparib and Temozolomide Combination Therapy in Clinical Trials for Advanced Malignancy (mg/m2)
Figure 17-2: Study of Veliparib + Temozolomide Showing Improved Survival of Patients with Metastatic Melanoma (Months)
Figure 17-3: Estimated Glioblastoma Treatment Cost for Temozolomide + PARP Inhibitor Therapy, (US$/Cycle)
Figure 17-4: Olaprib and Paclitaxel Combination Therapy Dosage Analysis for Metastatic Gastric Cancer (mg/Day and mg/m2/Day)
Figure 17-5: Olaprib and Paclitaxel Combination Therapy Dosage Analysis for Metastatic Gastric Cancer (Administration/Cycle)
Figure 17-6: Olaparib and Paclitaxel Combination Therapy Cost Analysis for Metastatic Gastric Cancer (US$/Cycle)
Figure 17-7: Overall Survival in Patients with Triple-Negative Breast Cancer Treated with Gemiciabine and Carboplatin Chemotherapy vs. Combination Therapy with Iniparib (Months)